Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales.
about
Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndromeDistal effect of amino acid substitutions in CYP2C9 polymorphic variants causes differences in interatomic interactions against (S)-warfarinCYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drugInvestigating the Role of Plasma Glucose Concentration as a Phenotypic Marker for CYP2C9 Genetic Variants, in the Diabetic Population of GujaratPharmacogenetic testing revisited: 5' nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19.Increased genetic diversity of ADME genes in African Americans compared with their putative ancestral source populations and implications for pharmacogenomics.No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.Association between genetic polymorphisms of cytochrome P450 2C19 and the risk of cerebral ischemic stroke in Chinese.Abuse liability of oxycodone as a function of pain and drug use history.Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort studyCYP2D6 and CYP2C19 in Papua New Guinea: High frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess.The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea.Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patientsPossible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsyDistribution of the most Common Genetic Variants Associated with a Variable Drug Response in the Population of the Republic of Macedonia.Lessons from pharmacogenetics and metoclopramide: toward the right dose of the right drug for the right patient.Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19.Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descentRisperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort.Cytochrome P450 2C9-CYP2C9.Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.Drug interactions in African herbal remedies.Pharmacogenomics and epilepsy: the road ahead.Cytochrome P450 variations in different ethnic populations.The role of pharmacogenetics in nonmalignant gastrointestinal diseases.Cytochrome P450 pharmacogenetics in African populations.African variation at Cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases.Priority pharmacogenetics for the African continent: focus on CYP450.The emerging era of pharmacogenomics: current successes, future potential, and challenges.Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations.Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes.Identification and analysis of mtDNA genomes attributed to Finns reveal long-stagnant demographic trends obscured in the total diversity.The global spectrum of protein-coding pharmacogenomic diversity.Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population.Human loci involved in drug biotransformation: worldwide genetic variation, population structure, and pharmacogenetic implications.Distribution of CYP2C19*2 and CYP2C19*3 polymorphisms in Venezuelan populations with different admixture.High prevalence of the GSTM3*A/B polymorphism in sub-Sarahan African populations.Characterization of the genetic profile of CYP2C19 in two South African populations.
P2860
Q26860280-CE3F6B41-64C3-41FB-900D-2743B7C49A5EQ28536483-B5DA0B88-5DCC-4532-BEC1-029821913000Q28544111-FF2AB416-E056-45D2-97A8-A9685DF4A7B3Q33555327-7E6ED0F0-AF03-4372-B13A-D5A4706A022BQ33597438-00B24E75-EB86-4638-99E2-D78ADE15DACDQ33613526-7870DE89-570A-4128-8BCD-CEC8F655D363Q33649116-9F13DF54-6309-43A7-8EE7-B4A0DFE933EBQ34010627-21116736-F87C-485C-A7FD-4835AEC172EFQ34051406-27B08AF8-D6A8-4146-B489-0C4C4F2298CEQ34273354-B5A4A081-D432-4A50-A604-AD27BF05216BQ34565428-88DF708A-5C58-49EB-992D-E8876484C65CQ34794075-DADE2AD0-51E5-4518-B316-E92D05E4C08BQ34969275-DDD27744-C16C-4F4E-9D71-C81B8A3490D5Q34976487-A8940FD7-F3E5-41D3-BCFD-3B13C5B57E1BQ35351731-0B0514CD-9A0D-4284-BC10-253635F12E0CQ35549639-770D4372-5632-4584-A31E-C13811E43B0DQ36028732-F9A11055-6993-48F0-A53A-DDD6CC9A90AEQ36307008-4A7FB5A5-4E4F-4870-B9E3-868E6512CF5EQ36384257-A6CBF507-D0A9-4E57-8FEE-BF2799CD8C2BQ36556433-C15CC2E7-5D8E-43EF-AB42-78E858B4D279Q37691210-0F15C307-8D8F-4A69-B317-EFB72431ECC5Q37715233-767FE785-6349-4C26-840D-516ABC349A10Q37901060-5CD95770-04A7-495D-A012-A076531DA2B7Q37946957-7FEB3A7C-250F-4F74-9695-AD833300A08DQ37979866-A6782062-9313-45CC-B15B-01E9271F97F1Q37981892-CBFC3B67-AF0A-468D-A086-21D131218F52Q38099372-C953554D-AFAF-45A1-B826-3486776C1EFAQ38183664-DCEDA4B9-5CC0-4E2F-9A5A-DCAF63615726Q38188600-45E92E78-66CF-4419-B04B-CC336B4D80C7Q38200683-E6455ABA-0EC3-430F-A29D-30145DA77B81Q38388873-682A118E-E63A-4D56-A501-59650AAE3C3FQ38616806-620655EA-20E5-479A-B9DF-10B91A719351Q38643436-FD377FD1-C849-4E72-85A9-9FA15FCDE5CFQ38667175-B00394BD-0B6A-4E75-9EE3-80B69E0AA0FFQ38806047-6724705B-24BA-4F61-BE3F-81323BE26527Q39065445-46070359-9E5F-46EF-B1A7-2E99B992FB94Q39203656-A28019B6-0A28-4EB9-8B99-28E25C0272F3Q39501603-ADBB1E69-68DE-46E1-B655-9F190576DDDAQ39515742-EAC219BC-976E-4373-A951-E2793AFBBB36Q39667176-846E119C-26B2-4052-98F9-5499D68D6521
P2860
Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Pharmacogenetic variation at C ...... al and microgeographic scales.
@en
Pharmacogenetic variation at C ...... al and microgeographic scales.
@nl
type
label
Pharmacogenetic variation at C ...... al and microgeographic scales.
@en
Pharmacogenetic variation at C ...... al and microgeographic scales.
@nl
prefLabel
Pharmacogenetic variation at C ...... al and microgeographic scales.
@en
Pharmacogenetic variation at C ...... al and microgeographic scales.
@nl
P2093
P1476
Pharmacogenetic variation at C ...... al and microgeographic scales.
@en
P2093
Johanna Sistonen
Jukka U Palo
Neelam Chauhan
Silvia Fuselli
P304
P356
10.1097/FPC.0B013E32831EBB30
P577
2009-02-01T00:00:00Z